Coeptis Therapeutics, Inc.
COEP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.34 | 0.51 | 0.02 | 0.00 |
| FCF Yield | -2.60% | -8.29% | -8.22% | -13.57% |
| EV / EBITDA | -31.51 | -7.13 | -8.73 | -4.28 |
| Quality | ||||
| ROIC | -1.18% | -50.91% | -41.94% | -38.44% |
| Gross Margin | 80.98% | 77.50% | 28.18% | 50.00% |
| Cash Conversion Ratio | 0.79 | 0.55 | 0.69 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 794,127.19% | 641,046.22% | 397,540.27% | -100.00% |
| Free Cash Flow Growth | 10.20% | -1.29% | -64.71% | 24.10% |
| Safety | ||||
| Net Debt / EBITDA | 1.94 | 0.17 | 0.73 | -0.32 |
| Interest Coverage | 39.56 | -66.70 | -56.75 | -27.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,528.22 | -2,037.04 | -2,233.57 | -122.65 |